Consequently, the development of anti-CD47 antibodies is warranted, and anti-CD47 therapy has been shown to enhance the efficacy of PD-1 and CTLA-4 inhibitors in esophageal squamous cell carcinoma (ESCC) (49, 50). This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.